U.S. markets closed
  • S&P 500

    3,719.04
    +71.75 (+1.97%)
     
  • Dow 30

    29,683.74
    +548.75 (+1.88%)
     
  • Nasdaq

    11,051.64
    +222.13 (+2.05%)
     
  • Russell 2000

    1,715.24
    +52.73 (+3.17%)
     
  • Crude Oil

    81.73
    -0.42 (-0.51%)
     
  • Gold

    1,666.40
    -3.60 (-0.22%)
     
  • Silver

    18.88
    0.00 (0.00%)
     
  • EUR/USD

    0.9726
    +0.0128 (+1.33%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • GBP/USD

    1.0865
    +0.0134 (+1.25%)
     
  • USD/JPY

    144.2180
    -0.5730 (-0.40%)
     
  • BTC-USD

    19,544.48
    +502.23 (+2.64%)
     
  • CMC Crypto 200

    447.10
    +18.32 (+4.27%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

·1 min read
  • Atara Biotherapeutics Inc (NASDAQ: ATRA) received notification that Bayer AG's (OTC: BAYRYintends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies.

  • The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors.

  • ATA3271 leverages Atara's EBV T-cell platform and is currently in IND (Investigational New Drug)-enabling studies.

  • Related: Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial.

  • Upon termination of the agreement in September 2022, Atara will have full rights to continue the clinical development and future commercialization of its programs worldwide.

  • Atara expects to provide a Phase 1 data update for ATA2271 in H2 2022 and will also continue to lead IND-enabling studies and process development for ATA3271.

  • "Given the exciting developments on ATA188 and tab-cel and our continued progress toward submitting an IND for ATA3219 in Q4 2022, we plan to focus our resources accordingly while re-assess our strategy for our mesothelin CAR T program," said Pascal Touchon, President and CEO of Atara.

  • "Consequently, we will postpone the anticipated IND filing for ATA3271 beyond the fourth quarter of 2022. We are also maintaining our cash runway guidance into Q4 of 2023," Touchon added.

  • Price Action: ATRA shares closed 14.3% lower at $4.42 during after-hours trading on Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.